Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: selpercatinib, alectinib, sorafenib tosylate +13 | 1.00 |
| trials ClinicalTrials.gov | 2 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 146 Parkinson's papers of 12,217 | 0.34 |
| pathways Reactome | 5 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 6040
Sealed predictions
- RET in dopamine neurons, braak-0.23 (p 0.549) → -0.44 (p 0.232)receipt 6048
In the sealed studies
Swarm cases
receipt 6048: RET in dopamine neurons, braak
- power
- full sample -0.25 (p 0.319, n 18), 95% CI -0.64 to +0.25. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.33 (p 0.188, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.56 (p 0.015, n 18). not the mix.
- skeptic
- leave-one-out range -0.36 to -0.15, sign flips 0; without severely affected donors -0.25 (p 0.319, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RET in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts